Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma

Next Previous
Trial Profile

A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Antineoplastics; Cyclophosphamide; Cytarabine; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-MCL0208

    • Most Recent Events

    • 15 Jun 2023 Status changed from active, no longer recruiting to completed according to results presented at the 28th Congress of the European Haematology Association
    • 15 Jun 2023 Final results of the Fil Mcl0208 Trial long-term clinical and molecular results at a median follow-up (mFU) of 84 months (M) fromenrolment and 74M from randomization, including four additional late MRD time points (M18, M24, M30, M36) presented at the 28th Congress of the European Haematology Association
    • 22 May 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Feb 2018).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top